Much as been made of the WSJ report on investment bank biotech commentators earning several million dollars of annual compensation. One should not be distracted. In the peak of every bull market, some participants will receive excessive rewards for no reason. This transient wealth transfer from an investment bank to an individual does not merit your envy. Once every ten years, if the excessive sum is even $5,000,000, net of taxes, the salary increase is $250,000 annually. Hardly worth getting out of bed for, let alone envying, given this excess applies only to the very few and one only has so many ten-year-cycles in his future. Indeed, do not stray for evanescent earnings–compounding is the only path.
Papers I’ve Read
Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Hao et al. J Med Chem 2018,61:5609-5622.
These workers produce a very potent and selective EGFR mutant:EGFR wildtype inhibitor but with very weak PK. I doubt this drug will see the light of day when compared to Tagrisso’s profile.
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Clement et al. Nature Medicine 2018.
Well, RYTM is a fascinating company with a fascinating drug, setmelanotide. I’m very familiar with the POMC class which includes Acthar, Synacthen, Clinuvel’s drug, this drug, non-peptide synthetics and other peptide agents. These genetic obesity illnesses are very rare, but the efficacy is profound. The small uncontrolled Phase 3 trials Rhythm are doing will probably “work”(though I’m a bit afraid of some tachyphylaxis or other weird physiological dynamics that occur in appetite control). On the business side, this is a daily drug. Clinuvel’s longer-acting compound probably will do the same thing clinically. The authors do some preclinical work demonstrating this drug engages the MC4R receptor a bit differently than alpha-MSH or a synthetic. I can believe that, I guess, but I wonder if this drug will last the test of time given all of this. Also consider metreleptin didn’t do too well for the same disease state. Fairly modest revenue for that drug, especially in context of RYTM market cap.
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors. Pfizer and Array BioPharma.
Can’t say I understand this trial. “When pharma has too many oncology drugs”.
Evaluation of the Safety and Efficacy of TLD in Patients with COPD. Nuvaira, Inc.
Interesting “targeted lung denervation” device. Wonder if it would help a friend I have who has lung problems.
Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial.
Cognitive Reserve and Second Language Acquisition.
I could use some of this “cognitive reserve”. Think mine is all gone.
Not a lot going on. Trashy is well. I am surprised this 8 pound marvel is able to handle all of my affairs so easily and still has time to sleep throughout the day. She could have commanded certain tasks to her canine companion, but his constant confused countenance certainly curtails the cat’s confidence in her confounded consort.